Anne Barmettler, MD, an associate professor of ophthalmology, visual sciences, and plastic surgery at Montefiore Medical Center, discusses the cost of teprotumumab for thyroid eye disease.
Although teprotumumab is the first treatment for thyroid eye disease to gain FDA approval, its cost has served as a barrier to treatment uptake by providers, said Anne Barmettler, MD, an associate professor of ophthalmology, visual sciences, and plastic surgery at Montefiore Medical Center.
Transcript
How has provider uptake of teprotumumab been since the drug's approval?
Teprotumumab is very exciting for both doctors and patients because it is the first drug available for thyroid eye disease. The issue with it is that it is extremely expensive, and it isn't just a medication that you can take easily. It's an infusion that has to be done every 3 weeks for 24 weeks. So it's a commitment and you need to have a way of getting that infusion into the patient. So that, plus the cost of the medication and monitoring for side effects has made it a little bit tougher for everyone to get this into their practice.
Has the steep price tag of teprotumumab stymied uptake?
Yes, the answer is definitely yes. So, for an average-sized adult the price tag is around $300,000 per person. Understandably, insurance companies are really hesitant to pay for this because they could treat a lot of other people with that same amount of money. So there have been a number of issues in place with insurance companies not wanting to cover this medication unless other treatments have been tried and failed, or certain exam criteria have been met and documented. Those are definitely things that are slowing down its use.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Detail Effects—and Uncertainty—of Drug Pricing Negotiations
May 7th 2024Research into the Inflation Reduction Act evaluated payer concerns, patient and physician behavior, which patients will benefit from the first 10 drugs selected for price negotiation, and the ripple effect into Medicaid at the state level.
Read More